Emerging Research in the Smoldering Myeloma Field with Dr. Kazandjian image

Emerging Research in the Smoldering Myeloma Field with Dr. Kazandjian

Jul 19, 2022
01:00PM - 02:00PM EDT
Online Event
Overview

Precursor multiple myeloma research is progressing and the results are exciting. Learn what's being done in the field from Dr. Dickran Kazandjian, a myeloma specialist at Sylvester Comprehensive Cancer Center in Miami. Come with your questions!

Agenda
01:00 PM
Introduction
Audrey Burton-Bethkee
Audrey introduces the agenda of the event and featured speaker Dr. Kazandjian.
01:05 PM
Presentation
Dr. Kazandjian
Dr. Kazandjian talks about precursor multiple myeloma research and the results.
01:35 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them!
Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Dickran Kazandjian, MD

Dickran Kazandjian, MD

Dr. Kazandjian’s clinical and translational research interests lie in the treatment of precursor plasma cell disorders including high risk smoldering multiple myeloma and the role of immunotherapy in plasma cell dyscrasias. In addition, he is re-evaluating the role of autologous stem cell transplant (ASCT) in the era of highly efficacious novel-novel drugs, immunotherapy biologics, and cell-based therapies with the hypothesis that certain subsets of patients with myeloma may not benefit by default upfront ASCT.